Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin / 한국유방암학회지

The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the efficacy of this strategy in male patients with TNBC. In this report, we describe a male patient with AR-positive TNBC who was successfully treated using an LHRH agonist after pretreatment with several lines of chemotherapy and achieved a durable response. We also review the existing evidence supporting LHRH- and AR-targeted therapy for this rare disease.

Use of temozolomide in the management of high grade gliomas at relapse.

This study was done at NEMROCK and other private as well as official governmental oncology centers, where 30 patients with residual or relapsed high grade gliomas received temozolomide at a dose of 200 mg/m2/day for five successive days to be recycled on day 21 for a total of six courses. Drug administration was quite safe with accepted toxicity profiles. The response parameters, including partial response, stationary disease and progressive neoplastic process, were documented in 33%, 45% and 22%, respectively

superiority of high dose chemotherapeutic regimens in the treatment of pediatric Non-Hodgkin's Lymphoma: results of a retrospective non randomized study of 103 evaluable cases

This retrospective study reviewed 160 previously untreated cases of pediatric Non Hodgkin's lymphoma referred to NEMPOCK between Jan. 1985-Dec. 1993. The treatment protocol adopted for these patients were the COMP regimen for undifferentiated, [small non cleaved], diffuse mixed and large cell subtypes while lymphoblastic lymphoma and T cell immunoblastic subtypes were treated by a modification of the CHOP regimen. During the study period 2 different dose levels of the treatment regimens were used: low dose regimens [1965-1989] and high dose regimens [1990-1993]. The response rate achieved among the 103 evaluable cases was significantly infavour of the high dose regimens being 85% and 86% for the COMP and CHOP respectively versus 57% and 60% [p< 0.05] for their low dose counter parts. C.N.S. relapse was seen in 10% with no significant benefit observed in patients received prophylactic cranial irradiation compared to those who received intrathecal chemotherapy alone. Relapse was reported in 9 out of the 70 cases who achieved complete remission [41%]. The relapse rate was reduced significantly [p=0.05] in patients treated by the high dose regimens compared to those treated by the low dose regimens [32% and 49% respectively]. A median follow up period of 64 months [range 24-129 months], the overall survival was significantly superior in patients treated by the high dose regimens compared to those treated by the low dose regimens being 59% and 31% respectively [p=0.03]. The following prognostic factors were significantly associated with poor prognosis: presence of bulky disease [p=0.0001], low dose regimens [p=0.007], stage IV disease [p=0.01] and initial CNS involvement [p=0.05]

Value of protocol treatment of pediatric non-Hodgkin's lymphoma

The present study included 77 cases of pediatric Non-Hodgikn's lymphoma [NHL]. Twelve patients had received precious treatment elsewhere and were referred for salvage treatment after relapse. The remaining 65 patients were fresh cases. Fifty five percent of the whole group presented in abdominal sites. The commonest histological type in this group was undifferentiated NHL. Lymphobloastic lymphoma was the most common histological subtype among extra-abdominal presentation. Thirteen patients did not attend to receive their full treatment program and were excluded from further analysis. Treatment was given either on protocol basis [33 cases] or on individual non protocol basis [19 cases]. Complete remission [C.R.] was achieved in 78.7% [26/33] in the protocol group versus 16% [3/19] in nonprotocol cases [P< 0.001]. No single case of C.R. could be obtained with salvage treatment. Details of treatment programs and their outcome are discussed

challenge of recurrent basal cell carcinoma

Recurrent basal Cell Carcinoma "B.C.C." is a much more difficult problem to diagnosis and to treat compared to primary B.C.C. In this work 35 cases of recurrent B.C.C. were studied to conclude the real reasons of recurrence to prevent and to establish an accurate way to follow up and to predict recurrences. A trial was made to choose the best way of ablative and reconstructive steps of treatment. Recurrence rate after treating recurrent B.C.C. in such series was 20% which is near the experience of other authors. This is much higher than the expected recurrences after treating primary B.C.C. Surgery was adopted in 27 cases and radiotherapy in 8 cases. the disease free survival rate at a mean period of 3 years as 81% and 75% for the groups treated by surgery and radiotherapy respectively. The highest rate of a second recurrences was observed in their morphed like lesions [four out of six cases] and lesions around fusion lines [five out of six].Post radiation recurrences were more difficult to predict and to treat; nevertheless the final disease free survival for such group was almost equal to the post surgery recurrences